The Danish drugmaker presented the new long-term data on Tuesday at the European Congress on Obesity in Venice, Italy, in a new analysis from a large study for which substantial results had been published last year. “This is the longest study we’ve conducted so far of semaglutide for weight loss,” Martin Holst Lange, Novo’s head of development, said in an interview, referring to the active ingredient in Wegovy and the company’s diabetes drug Ozempic.
Participants were not required to track diet and exercise because it was not an obesity study. Around 17% of trial participants stopped using Wegovy due to side effects, the most common of which was nausea, Novo said in another analysis in the trial published by the drugmaker on Tuesday. Patients in the trial, called Select, lost an average of nearly 10% of their total body weight after 65 weeks on Wegovy.
Source: Healthcare Press (healthcarepress.net)
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »
Source: futurism - 🏆 85. / 68 Read more »
Source: nbcsandiego - 🏆 524. / 51 Read more »
Source: CNBC - 🏆 12. / 72 Read more »
Source: ABC - 🏆 471. / 51 Read more »
Source: CNBC - 🏆 12. / 72 Read more »